Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031

The global pharmaceutical industry is undergoing a significant transformation, according to a new analysis by Frost & Sullivan. Companies that can accelerate their innovation processes, scale up new discoveries effectively, and manage increasing pressures from pricing regulations and international politics will likely lead the market. Key drivers shaping the industry's future include advancements in artificial intelligence, the growing importance of biologic drugs, and the need for robust and resilient supply chains. These factors are expected to redefine growth trajectories through 2031.

This industry reset is crucial as it will determine which companies are best positioned to deliver future medical advancements and ensure drug accessibility amidst complex global challenges.